Kennedy seeks to be Secretary of Health and Human Services — a position that would put him in charge of the health of the American people.

On 23 January, Elevance Health (ELV) increased its quarterly dividend by 4.91%, from $1.63 to $1.71 per share. The dividend is payable on 25 March to shareholders of record on 10 March.

Check out these three health-tech stocks with prospects of recovery in 2025 after seeing shares decline significantly in 2024.

The firm’s medical-loss ratio (MLR) rose to 92.4% due to Medicaid-related costs but was better than expected.

Elevance Health Q4 revenues hit $45 billion, driven by premium growth and acquisitions. 2025 EPS guidance is $34.15-$34.85, with a $1.71 dividend declared.

Elevance Health, Inc. (NYSEELV) reported fourth quarter and full year 2024 results.

Many stocks flashed buy signals as the major indexes rose to or above key levels.

The Dow giant earnings beat Q4 views, but revenue missed and medical costs ran high.

Shares of insurers and pharmacy benefit manager (PBM) companies such as Centene, Elevance Health, Humana and CVS Health are trading lower Thursday, likely in reaction to UnitedHealth Group's disappointing fourth-quarter 2024 revenue results.

As of Jan. 7, 2025, UnitedHealth Group is the country’s most valuable insurance company, with a market cap of $473 billion.

Elevance Health (NYSEELV) will release fourth quarter and full year 2024 financial results on January 23, 2025, at 6:00 a.m. Eastern Standard Time (“EST”). Management will review these results and its outlook during a conference call at 8:30 a.m. EST that same morning. The conference call should be accessed at least 15 minutes prior to its start with the following numbers:

U.S. healthcare spending grew 7.5% to $4.9 trillion in 2023, with hospital care and prescription drugs driving costs. Private insurance accounted for 30% of total spending.

Discover why HCA Healthcare stock could be poised for a recovery despite recent setbacks, including hurricane-related expenses and claim denials.

SAN DIEGO, Dec. 11, 2024 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins LLP is investigating Elevance Health Inc. (NASDAQELV) to determine whether certain Elevance officers and directors violated securities laws and breached fiduciary duties to shareholders. Elevance is a healthcare company that supports consumers, families, and communities across the entire care journey.

AM Best has affirmed the Financial Strength Rating (FSR) of A (Excellent) and the Long-Term Issuer Credit Ratings (Long-Term ICRs) of “a+” (Excellent) of the core Blue Cross Blue Shield (BCBS)-branded insurance subsidiaries of Elevance Health, Inc. (Elevance) (Indianapolis, IN) [NYSE: ELV], as well as its life insurance subsidiaries. These companies collectively are referred to as Anthem Health. At the same time, AM Best has affirmed the Long-Term ICR of “bbb+” (Good), the Long- and Short-Term Issue Credit Ratings (Long-Term IR; Short-Term IR) of Elevance and the Long-Term IR on the existing surplus notes of Anthem Insurance Companies, Inc. (Indianapolis, IN).